HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Investors pour $115M into RQ Bio in search of a preventive flu drug

The startup claims to have a "differentiated" antibody that can provide long-lasting protection against a variety of influenza strains.

By BioPharma Dive · Jun 24, 2026 · via BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca spells out a community cancer screening strategy with the YMCA
AstraZeneca has partnered with YMCA of the USA to increase awareness of cancer screening and early detection.…
Jun 25, 2026
Spurned by FDA, Passage Bio finds exit through merger with Remix
The WeekFierceBiotech ↗
Spurned by FDA, Passage Bio finds exit through merger with Remix
Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year aft…
Jun 25, 2026
Gilead’s Trodelvy Wins Broad Front-Line TNBC Nod, Escalating TROP2 ADC Competition
The WeekBriefing
Gilead’s Trodelvy Wins Broad Front-Line TNBC Nod, Escalating TROP2 ADC Competition
The FDA approved Trodelvy for first-line triple-negative breast cancer regardless of PD-L1 status, days after …
Jun 25, 2026